Biologics for eosinophilic oesophagitis: a systematic review . . . Nhu QM, Aceves SS Current state of biologics in treating eosinophilic esophagitis Ann Allergy Asthma Immunol 2023;130(1):15–20 doi: 10 1016 j anai 2022 10 004 [Google Scholar] 43 Avlas S, Shani G, Rhone N, et al Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis
Current state of biologics in treating eosinophilic esophagitis Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated, eosinophil-predominant, type 2 inflammatory disease that progresses to fibrostenosis of the esophagus if left untreated This review focuses on biologics therapy in EoE
Biologics in the Treatment of Eosinophilic Esophagitis: Ready . . . Eosinophilic esophagitis (EoE) is a chronic disease mediated by environmental allergens and type 2 immune inflammation, which causes significant symptoms including dysphagia and food impaction 1,2 The incidence and prevalence of EoE are rising and untreated disease can lead to significant esophageal stenosis 2,3 Standard treatments include proton-pump inhibitors (PPIs), swallowed topical
The Dupixent as a Treatment for Eosinophilic Esophagitis Dupixent as a Treatment for Eosinophilic Esophagitis Eosinophilic esophagitis (EoE) is a long-term inflammatory disorder of the esophagus, leading to symptoms like difficulty swallowing, chest discomfort, and food impaction Without proper treatment, it can greatly diminish quality of life
Biologics in eosinophilic esophagitis - PubMed Purpose of review: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus whose incidence is on the rise Despite maximal use of guideline-based therapies including food elimination diets and steroids, many patients remain symptomatic